{"transactions":[{"id":740069,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T00:42:07.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":56549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":56549,"derivative":{"exercise_price":14.09,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":56549},"source":{"system":"sec-edgar","filing":"0001193125-26-270000","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526270000/ownership.xml","form_type":"4"}},{"id":1084085,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:45:46.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26400,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":96.57,"underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001104659-25-069383","document":"tm2521348-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000110465925069383/tm2521348-15_4seq1.xml","form_type":"4"}},{"id":1084084,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:45:46.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":95.12,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-069383","document":"tm2521348-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000110465925069383/tm2521348-15_4seq1.xml","form_type":"4"}},{"id":1084083,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:45:46.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":43.15,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-069383","document":"tm2521348-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000110465925069383/tm2521348-15_4seq1.xml","form_type":"4"}},{"id":1084082,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:45:46.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":61.31,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-069383","document":"tm2521348-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000110465925069383/tm2521348-15_4seq1.xml","form_type":"4"}},{"id":1084081,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:45:46.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":100.13,"underlying":"Common Stock","underlying_shares":26125},"source":{"system":"sec-edgar","filing":"0001104659-25-069383","document":"tm2521348-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000110465925069383/tm2521348-15_4seq1.xml","form_type":"4"}},{"id":1084080,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:45:46.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":93.93,"underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001104659-25-069383","document":"tm2521348-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000110465925069383/tm2521348-15_4seq1.xml","form_type":"4"}},{"id":1084079,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2025-07-21T19:45:46.000Z","date":"2025-07-17","kind":"other","planned":false,"acquired":false,"shares":31956,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-069383","document":"tm2521348-15_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000110465925069383/tm2521348-15_4seq1.xml","form_type":"4"}},{"id":1084078,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2025-07-21T19:45:46.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":83281,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions (\"PSUs\"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (\"RSU\"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award."}],"balance_after":31956,"source":{"system":"sec-edgar","filing":"0001104659-25-069383","document":"tm2521348-15_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000110465925069383/tm2521348-15_4seq1.xml","form_type":"4"}},{"id":1084077,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2025-07-21T19:45:46.000Z","date":"2025-07-17","kind":"grant","planned":false,"acquired":true,"shares":39456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions (\"PSUs\"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award."}],"balance_after":115237,"source":{"system":"sec-edgar","filing":"0001104659-25-069383","document":"tm2521348-15_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000110465925069383/tm2521348-15_4seq1.xml","form_type":"4"}},{"id":1135493,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T21:45:05.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":30000,"derivative":{"exercise_price":0.1868,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-014525","document":"form4-05232025_050501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925014525/form4-05232025_050501.xml","form_type":"4"}},{"id":1217558,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2025-03-07T16:13:30.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":6489,"price":88.8,"value":576223.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":75781,"source":{"system":"sec-edgar","filing":"0001415889-25-007402","document":"form4-03072025_090326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588925007402/form4-03072025_090326.xml","form_type":"4"}},{"id":1229215,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T17:16:32.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2025 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":26400,"derivative":{"exercise_price":96.57,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001415889-25-006602","document":"form4-03042025_100327.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588925006602/form4-03042025_100327.xml","form_type":"4"}},{"id":1229214,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2025-03-04T17:16:32.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of grant of 13,200 restricted stock units under the Issuer's 2024 Stock Incentive Plan."}],"balance_after":82270,"source":{"system":"sec-edgar","filing":"0001415889-25-006602","document":"form4-03042025_100327.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588925006602/form4-03042025_100327.xml","form_type":"4"}},{"id":1390825,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2024-10-04T17:09:38.000Z","date":"2024-10-03","kind":"sale","planned":false,"acquired":false,"shares":3633,"price":89.32,"value":324499.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average price. The shares were sold in multiple transactions ranging from $88.44 to $89.32.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2)."}],"balance_after":69070,"source":{"system":"sec-edgar","filing":"0001415889-24-024776","document":"form4-10042024_091035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588924024776/form4-10042024_091035.xml","form_type":"4"}},{"id":1500564,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-28T20:10:28.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 23, 2025 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject\nto the Reporting Person's continued service as a director through such date."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-014651","document":"form4-05282024_040524.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924014651/form4-05282024_040524.xml","form_type":"4"}},{"id":1530636,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-02T20:40:34.000Z","date":"2024-04-30","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on April 30, 2024, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":60000,"derivative":{"exercise_price":1.72,"expiration_date":"2034-04-29","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-24-012004","document":"form4-05022024_080527.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924012004/form4-05022024_080527.xml","form_type":"4"}},{"id":1584352,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2024-03-11T18:20:04.000Z","date":"2024-03-07","kind":"sale","planned":false,"acquired":false,"shares":4377,"price":90.69,"value":396950.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":72703,"source":{"system":"sec-edgar","filing":"0001415889-24-007554","document":"form4-03112024_100358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588924007554/form4-03112024_100358.xml","form_type":"4"}},{"id":1591934,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T16:21:43.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2024 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":30000,"derivative":{"exercise_price":95.12,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-007021","document":"form4-03062024_090337.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588924007021/form4-03062024_090337.xml","form_type":"4"}},{"id":1591933,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2024-03-06T16:21:43.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of grant of 15,000 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":77080,"source":{"system":"sec-edgar","filing":"0001415889-24-007021","document":"form4-03062024_090337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588924007021/form4-03062024_090337.xml","form_type":"4"}},{"id":1764365,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2023-10-05T10:47:33.000Z","date":"2023-10-04","kind":"sale","planned":false,"acquired":false,"shares":3769,"price":48.06,"value":181138.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $47.86 to $48.06 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":62080,"source":{"system":"sec-edgar","filing":"0001415889-23-014022","document":"form4-10052023_021027.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588923014022/form4-10052023_021027.xml","form_type":"4"}},{"id":1963472,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2023-03-08T21:34:49.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":63,"price":44.36,"value":2794.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $43.96 to $44.39 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":65849,"source":{"system":"sec-edgar","filing":"0001415889-23-004564","document":"form4-03092023_020342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588923004564/form4-03092023_020342.xml","form_type":"4"}},{"id":1963471,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2023-03-08T21:34:49.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":1885,"price":45.72,"value":86182.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":65912,"source":{"system":"sec-edgar","filing":"0001415889-23-004564","document":"form4-03092023_020342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588923004564/form4-03092023_020342.xml","form_type":"4"}},{"id":1974393,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T20:09:21.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2023 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":30000,"derivative":{"exercise_price":43.15,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-23-004262","document":"form4-03042023_010311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588923004262/form4-03042023_010311.xml","form_type":"4"}},{"id":1974392,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2023-03-03T20:09:21.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of grant of 15,000 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":67797,"source":{"system":"sec-edgar","filing":"0001415889-23-004262","document":"form4-03042023_010311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588923004262/form4-03042023_010311.xml","form_type":"4"}},{"id":2142324,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2022-10-05T18:54:36.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":3477,"price":67.3,"value":234002.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":52797,"source":{"system":"sec-edgar","filing":"0001415889-22-010366","document":"form4-10052022_031027.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588922010366/form4-10052022_031027.xml","form_type":"4"}},{"id":2344865,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2022-03-08T16:06:04.000Z","date":"2022-03-07","kind":"sale","acquired":false,"shares":1047,"price":56.19,"value":58830.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.18 to $56.90 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":56274,"source":{"system":"sec-edgar","filing":"0001415889-22-002738","document":"form4-03082022_040339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588922002738/form4-03082022_040339.xml","form_type":"4"}},{"id":2355178,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T19:59:51.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2022 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":30000,"derivative":{"exercise_price":61.31,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-22-002432","document":"form4-03032022_040334.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588922002432/form4-03032022_040334.xml","form_type":"4"}},{"id":2355177,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, R & D"}}],"security":"Common Stock","published_at":"2022-03-03T19:59:51.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of grant of 15,000 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":57321,"source":{"system":"sec-edgar","filing":"0001415889-22-002432","document":"form4-03032022_040334.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000141588922002432/form4-03032022_040334.xml","form_type":"4"}},{"id":2546497,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R & D"}}],"security":"Common Stock","published_at":"2021-10-07T16:26:00.000Z","date":"2021-10-05","kind":"sale","acquired":false,"shares":3241,"price":98.18,"value":318201.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":42321,"source":{"system":"sec-edgar","filing":"0001179110-21-009297","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000117911021009297/edgar.xml","form_type":"4"}},{"id":2647964,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-01T18:58:01.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":22750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":22750,"derivative":{"exercise_price":4.88,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":22750},"source":{"system":"sec-edgar","filing":"0001567619-21-012871","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000156761921012871/doc1.xml","form_type":"4"}},{"id":2647963,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T18:58:01.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":4610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4610,"source":{"system":"sec-edgar","filing":"0001567619-21-012871","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000156761921012871/doc1.xml","form_type":"4"}},{"id":2814513,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-03T16:15:01.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":26125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":26125,"derivative":{"exercise_price":100.13,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":26125},"source":{"system":"sec-edgar","filing":"0001179110-21-002645","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000117911021002645/edgar.xml","form_type":"4"}},{"id":2814512,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R & D"}}],"security":"Common Stock","published_at":"2021-03-03T16:15:01.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":13062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of 13,062 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":45562,"source":{"system":"sec-edgar","filing":"0001179110-21-002645","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000117911021002645/edgar.xml","form_type":"4"}},{"id":3013644,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-05T16:16:25.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 25% of the shares underlying the option on October 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":65000,"derivative":{"exercise_price":93.93,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001179110-20-010225","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000117911020010225/edgar.xml","form_type":"4"}},{"id":3013643,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R & D"}}],"security":"Common Stock","published_at":"2020-10-05T16:16:25.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of 32,500 restricted stock units under the Issuer's 2020 Inducement Plan."}],"balance_after":32500,"source":{"system":"sec-edgar","filing":"0001179110-20-010225","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000117911020010225/edgar.xml","form_type":"4"}},{"id":3097712,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":38788,"kind":"person","name":"Namouni Fouad","position":1,"cik":"0001815851","reported_name":"Namouni Fouad","relationship":{"director":true}}],"security":"Stock Option (right to Buy)","published_at":"2020-06-29T18:05:15.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on June 26, 2021 subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":7000,"derivative":{"exercise_price":38.32,"expiration_date":"2030-06-26","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000905148-20-000733","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815851/000090514820000733/form4.xml","form_type":"4"}}]}